We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.25 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.25 | GBX |
York Pharma (YRK) Share Charts1 Year York Pharma Chart |
|
1 Month York Pharma Chart |
Intraday York Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/8/2009 | 10:10 | York Pharma - a hot pharma for 2005 | 2,999 |
| 03/3/2009 | 15:54 | BOMBED OUT STOCK THAT COULD EXPLODE IN 2009 | 16 |
| 14/11/2004 | 16:36 | new issue | 2 |
| 14/11/2004 | 15:47 | York Pharma - New to the Market : 26th April 2004 | 140 |
| 10/9/2004 | 15:40 | mile | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 28/7/2009 17:17 by wetdream Hey guys, having lost about £5 in YRK how do I go about offsetting these losses for CGT purposes against gains elsewhere, if the shares aren't tradable?TIA. |
Posted at 27/7/2009 20:54 by topvest The end of YRK. It took a while, but unfortunately this looked inevitable. Sadler made the same mistake as Bioglan and borrowed, even though he said he wouldn't make the same error again! We never heard about Abasol did we. Some high profile investors lost their shirt on this. I managed to break-even which is better than most. Had no shares left at the end. We've all learnt a lesson on this one though. Bioshark was correct. I'd love to know the truth on Abasol formally, but guess we will never know unless the administrators report (issued in a month or two normally) tells the real story! |
Posted at 20/7/2009 21:56 by topinfo 8Trade, thank you for those kind words, Im starting to like you again. I was very bullish on YRK and I have spoken on several occasions to someone at the company whilst shares suspended and although they didnt and couldnt give loads away due to FSA rules etc they hinted at being very optomistic. I hope my recent thoughts are unfounded but the longer it takes the more bearish I am becoming. I like most on here stand to lose and that gets me as this was once a great company and I thought RA could turn it around...maybe just maybe he will prove me wrong.? |
Posted at 16/7/2009 07:24 by topinfo Kiki...You have been busy, sounds okay but I still think if deal with ULU was worth around 6p per share and RA thought this deal was much better for shareholders then I would assume a starting share price of well above that 6p figure IMHO. |
Posted at 15/7/2009 00:11 by topinfo Backinblack. I have offered an olive branch many times before but he declines to kiss and make up and continues to slate me so ce la vie. Anyway back to YRK yep I am expecting something this week as deadline for paying back ULU etc is 22nd July I think so things should be sorted one way or another. This can only have 2 outcomes and one of course is we lose the lot and YRK vanishes into thin air, alternatively they come back to mkt fully financed up/merged/RTO etc, in which case we will get a massive rise in the share price ..Its 50/50 now I feel as things seem to be dragging out and I am starting to question whether my source at YRK has been telling me the Gods honest truth or not...we shall see soon.!! |
Posted at 05/7/2009 11:28 by topinfo Nobby. Why what makes you think not this week? Also York was priced to go bust, if these come back they will rise significantly. Mkt cap ridiculous compared to potential products. They turned down deal with ULU that valued York at around 6p per share, they did this as the other deal was better for shareholders so makes sense for share price to rise significantly above that 6p price.. I have spoken to RA at length as well and I get the feeling this deal will be very very well received by the city.!! |
Posted at 18/6/2009 14:37 by topinfo KiKi...Not long to wait now, they will be back soon. Just remember this was priced to go bust, either we get fully taken over or Re-Financed, either way share price will go up significantly. Looking at ULU I would rather go for the re-financing deal and that way the new CEO Richard Anderson who is the biggest single shareholder can rebuild the business and return real value to shareholders. If it comes back then it will be one of two deals as mentioned, either or will have massive impact on share price I personally would like to see option 2. |
Posted at 07/6/2009 08:04 by kiki14p Thanks Topinfo & BB80 reassuring comments..Not spoken to RA but heard it all before from previous CEO... TS in conversation was also very very optimistic about the company (maybe too much!) - won't again base my investment decisions on how enthusiastic a director is, does not mean they can pull it off and grow the company and share price on enthusiasm alone! |
Posted at 13/5/2009 12:56 by topinfo Good news at least. What the CEO is saying is accept the offer as shareholders otherwise he cant guarantee a satisfactory return to shareholders and they will need to raise funds. Well if its a case of take the offer or decline it I will take it as something is better than nothing. I bought quite low so am okay but feel for those who have put huge sums in over past few years, but at least this way you do get something back if takeover goes ahead. The new CEO has a large shareholding so will obvioulsy do His best to get as much as possible for shareholders.TIDMYRK RNS Number : 1382S York Pharma plc 12 May 2009 ? 12 May 2009 York Pharma plc (YRK.L) ("York" or the "Company") Restructure update and divestment of French subsidiary In January 2009, York announced that its newly appointed management team was conducting a strategic review to investigate options to restructure the Company's operations. Following completion of the review, the Board has now decided to simplify the ownership of its international distribution partnership network. This is being achieved through the reorganisation of the group's operations in France, Belgium and Luxembourg (the "Territory"), resulting in the divestment today of its 51% owned OTC focused subsidiary, ACM Crawford SAS ("ACM"), to ACM's minority shareholders, Thierry Leveillé and Sebastien Baudinot (the "Minority Shareholders"). ACM will continue to represent the Company as exclusive distributor in the Territory focused on the marketing of York's prescription brands. Background to divestment The Company's 51% interest in ACM was acquired as one of the assets of Derms Development Limited in November 2007. ACM is a sales and marketing business, which has been engaged in selling the Company's products in the Territory and which took prime responsibility for managing the Company's international distributor network. ACM had also developed a range of dermacosmetic products which it marketed principally in France. The various rights and management responsibilities of each of the Company and the Minority Shareholders in relation to ACM were set out in a Shareholders' Agreement entered into at the time of the establishment of the joint ownership and subsequently modified by the parties during 2008 (the "SHA"). The SHA contained provisions creating an obligation on the Company to acquire the outstanding minority interest in ACM of 49% for a pre-agreed aggregate amount of EUR6.25m. The SHA provided that any failure by the Company to complete the acquisition and remit the requisite payments in relation to the minority stake on time would entitle the Minority Shareholders to trigger a call option, enabling them to acquire the Company's 51% shareholding in ACM for a nominal sum of EUR2,550 (representing an amount of EUR10 per share) and to the write off of all intercompany debts owed by ACM to the Company. Divestment of ACM As the next step in implementing the revised corporate strategy, the Company has negotiated and entered into a separation agreement with ACM, the key terms of which are as follows: * An amount of EUR777,000 standing to the balance of an inter-company debt owed by ACM to the Company has, with effect immediately prior to the conduct of the separation, been capitalised through the issuance of 10,500 shares in ACM to the Company; * The Company's aggregate interest in ACM (comprising its initial 51% shareholding together with the additional 10,500 new shares in ACM mentioned above) was acquired as of today by the Minority Shareholders for a total of EUR23,661 in cash; * The balance of all and any intercompany debt owed by ACM to the Company, totalling in aggregate EUR51,795 has been forgiven; * The Company's existing rights and interest in two non-prescription dermacosmetic products, Vitix and Viticolor, have been transferred to ACM; * Any and all interests held by ACM in the prescription product Zindaclin and in the Company's international network of distributors have been transferred to the Company; * The Company has appointed ACM as its exclusive distributor for three years in the Territory; * ACM has granted the Company an option to distribute its products in the US market; and * ACM will provide support for future product acquisitions on a success fee basis. As a result of completing the divestment of its interest in ACM, the Company will be a prescription dermatology and skin care business, selling products directly in the UK market and through an international network of distributors covering 70 countries. Whilst the divestment will result in a lower annual rate of sales for the Company, it is expected to have a minimal impact on the group's results (after accounting for the minority interest) and will save the Company from the requirement to fund the previously agreed purchase price for the minority interest of EUR6.25m. The Company's last set of published results was for the interim period of six months ended on 31 March 2008. The unaudited net assets of ACM at 30 September 2008 were GBP78,811 and its unaudited revenues and loss before taxation for the eleven months ended 30 September 2008 were GBP2,809,189 and GBP191,748 respectively (Source: Company Management Accounts). After careful deliberation, the Directors consider, having consulted with the Company's Nominated Adviser, that the terms of the divestment of ACM are fair and reasonable insofar as its shareholders are concerned. Update on possible offer On 30 March 2009, the Company announced that it had entered into an agreement with Uluru Inc. ("Uluru") under which Uluru has provided the Company with a secured revolving credit facility and on 6 April 2009 the Company further announced that it had also signed a non-binding offer letter with Uluru for Uluru to acquire the Company. Drawdown of the credit facility is required to allow the Company to continue trading through the period needed to complete any formal offer for the Company under the Takeover Code. In accordance with the requirements of the Takeover Panel, Uluru has been notified of the divestment of ACM and has confirmed that, in accordance with Rule 21 of the Takeover Code, it does not consider the divestment to constitute a frustrating action in relation to the current ongoing discussions between the parties. The Board stresses that there can be no certainty that the discussions between the Company and Uluru will lead to an offer being made for the Company. In the event that no offer is made for the Company, it will need to raise additional capital to fund its operating activities and to repay indebtedness in due course. Shareholders should be aware that if the offer is not completed or if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations. The Company will provide a further update as and when appropriate. Richard Anderson, Chief Executive of York said: "We are pleased that following the conclusion of this restructuring, the Company will continue to work with ACM in Continental European markets. The settlement which we have negotiated enables us to move forward and exploit fully our international Zindaclin franchise, whilst protecting the Company and its shareholders from the uncertainty which would have arisen as a result of the contractual obligation of the Company to acquire the minority interest becoming due." For more information please contact: +------------------- | York Pharma plc | Tel: +44 (0) 1908 764020 | | Richard Anderson, Chief Executive | | | Officer | | | Ian Miscampbell, Chief Financial | | | Officer | | +------------------- | Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 | | Hugh Field / Adam Cowen | | +------------------- | FinnCap | Tel: +44 (0) 207 600 1658 | | Geoff Nash | | +------------------- | Financial Dynamics | Tel: +44 (0) 207 831 3113 | | Ben Brewerton / Emma Thompson | | +------------------- Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as Nominated Advisor and broker to York Pharma plc and will not be responsible to anyone other than York Pharma plc for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with any other matter referred to herein. About York Pharma PLC York Pharma is a pharmaceutical Group, established in 2003, which develops, markets and supplies branded dermatological products to pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology. |
Posted at 14/1/2009 10:03 by jpendle Completely incompetent management - share price didn't benefit from the deal announcement but has crashed as it failed.How can they unraved to sales - and what about any investment YRk made during their periond of control Where does the strategic review take us - they may have spent all their cask now - no wonder the market ignores the shares. Even if the company announces good news over the coming months it will now benefit the share price because it will have a large ? mark over it - directors need changing before we can move on. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
